Loading...
•
Mar 31, 2024
Supernus Q1 2024 Earnings Report
Reported strong Qelbree growth and total revenues, while managing operating losses.
Key Takeaways
Supernus Pharmaceuticals reported Q1 2024 financial results, with total revenues of $143.6 million and a net income of $0.1 million. Qelbree net sales increased by 75% compared to Q1 2023. The company reiterated its full-year 2024 financial guidance.
Qelbree net sales increased 75% to $45.1 million compared to Q1 2023.
Total revenues were $143.6 million.
Operating loss was $(3.2) million; adjusted operating earnings (non-GAAP) were $22.3 million.
Full year 2024 financial guidance reiterated, including total revenue guidance of $580 million to $620 million.
Revenue by Segment
Forward Guidance
The Company reiterates its full year 2024 financial guidance.
Positive Outlook
- Total revenues are expected to be between $580 million and $620 million.
- Combined R&D and SG&A expenses are projected to be between $430 million and $460 million.
- Operating loss is expected to be between $(30) million and $0 million.
- Adjusted operating earnings (non-GAAP) are projected to be between $80 million and $110 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...